Nemocnice AGEL Novy Jicin a.s. — Clinical Trial Site

69 Registered trials

33 Currently recruiting

Organisation

Nemocnice AGEL Novy Jicin a.s.

Location

Novy Jicin, Czechia

Identifier

ORG-100041104

Address

Purkynova 2138/16, 741 01, Czechia

Departments

1201: Onkologicke oddeleni
2004:Ortopedicko-traumatologicke oddeleni
Complex Oncology Center
Complex Oncology Center, Department of Oncology and Radiotherapy
Department of Dermatology
Department of Radiotherapy and Oncology
Dermatology
Hemodialýza
Hemodialyzační ambulance
Klinika gynekologie
Komplexní onkologické centrum
Komplexní onkologické centrum Oddělení radioterapie a onkologie
Komplexni onkologicke centrum Oddeleni onkologie a radioterapie
Komplexní onkologické centrum, Oddělení onkologie a radioterapie
Kožní oddělení se stacionářem
N/A
Nefrologicke oddeleni a hemodialyza
Nephrology and Hemodialysis Department
Oddělení nefrologie a hemodialýzy
Oddělení onkologie a radioterapie
Oddělení radiologie a onkologie
Oddělení radioterapie
Oddělení radioterapie a onkologie

Clinical trials at this site (69)

Search interface

A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants with mHSPC Ended

2023-508607-20-00 Metastatic Hormone-sensitive Prostate Cancer 5 2015-11-27
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Moderate to Severe Plaque Psoriasis 5 2025-09-16
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig… Ended

2023-508356-19-00 Pancreatic adenocarcinoma metastatic 4 2024-06-25
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended

2023-507559-30-00 Knee Osteoarthritis 4 2021-11-09
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended

2023-503898-38-00 Atopic Dermatitis 5 2019-05-24
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3… Ended

2022-501251-81-00 Renal cell carcinoma 5 2017-06-08
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall… Ended

2024-512477-27-00 Advanced Epithelial Ovarian Cancer (including Fallopian 4